The secretion of amyloid β-peptides is inhibited in the tacrine- treated human neuroblastoma cells

Debomoy Lahiri, Martin Farlow, Kumar Sambamurti

Research output: Contribution to journalArticle

72 Citations (Scopus)

Abstract

The amyloid β-protein (Aβ) is an approximately 4 kD secreted protein normally found in human plasma and cerebrospinal fluid. Aβ is invariably deposited as insoluble amyloid fibrils in the brains of patients with Alzheimer's disease (AD), and there is increasing evidence that Aβ deposition plays an important role in AD pathogenesis. Aβ is released from the larger β-amyloid precursor protein (βAPP) through cleavage on the amino and carboxyl side of Aβ by proteolytic activities referred to as β and γ secretase, respectively. βAPP is also cleaved at Aβ16 by a third protease, α secretase, which may prevent amyloid deposition by bisecting the Aβ peptide. Tacrine, a cholinesterase inhibitor, has been shown to improve memory and cognitive functions in some patients with AD, and we have previously demonstrated that it significantly reduces the levels of the secretion of soluble βAPP fragments (sAPP) in cultured cells. In this study, we extended our studies by analysis of Aβ40 and Aβ42 and report that in a human neuroblastoma cell line tacrine reduced the levels of total Aβ, Aβ40 and Aβ42 in addition to sAPP. These inhibitory results cannot be attributed to a reduction in total βAPP synthesis as tacrine treatment did not cause a significant change in the rate of βAPP synthesis. Furthermore, significant toxicity was not observed in tacrine-treated cultures as determined by analysis of lactate dehydrogenase (LDH) in the conditioned media. Taken together, these results suggest that tacrine affects the processing of βAPP by alterations in βAPP trafficking and/or increased intracellular proteolysis. This study raises the possibility that tacrine may aid in the treatment of AD due to its effects on βAPP processing as well as by its effects on the cholinergic pathway.

Original languageEnglish
Pages (from-to)131-140
Number of pages10
JournalMolecular Brain Research
Volume62
Issue number2
DOIs
StatePublished - Nov 26 1998

Fingerprint

Tacrine
Amyloid beta-Protein Precursor
Neuroblastoma
Amyloid
Peptides
Alzheimer Disease
Amyloid Precursor Protein Secretases
Serum Amyloid A Protein
Cholinesterase Inhibitors
Protein Transport
Conditioned Culture Medium
L-Lactate Dehydrogenase
Cognition
Cholinergic Agents
Proteolysis
Cerebrospinal Fluid
Cultured Cells
Peptide Hydrolases
Cell Line
Brain

Keywords

  • β- Peptide
  • β-Amyloid precursor protein
  • Alzheimer's disease
  • Anticholinesterase
  • Neuroblastoma cell
  • Protein processing
  • Protein transport
  • THA

ASJC Scopus subject areas

  • Molecular Biology
  • Cellular and Molecular Neuroscience

Cite this

The secretion of amyloid β-peptides is inhibited in the tacrine- treated human neuroblastoma cells. / Lahiri, Debomoy; Farlow, Martin; Sambamurti, Kumar.

In: Molecular Brain Research, Vol. 62, No. 2, 26.11.1998, p. 131-140.

Research output: Contribution to journalArticle

@article{a75bd0c227c24c6f8e398529d7385035,
title = "The secretion of amyloid β-peptides is inhibited in the tacrine- treated human neuroblastoma cells",
abstract = "The amyloid β-protein (Aβ) is an approximately 4 kD secreted protein normally found in human plasma and cerebrospinal fluid. Aβ is invariably deposited as insoluble amyloid fibrils in the brains of patients with Alzheimer's disease (AD), and there is increasing evidence that Aβ deposition plays an important role in AD pathogenesis. Aβ is released from the larger β-amyloid precursor protein (βAPP) through cleavage on the amino and carboxyl side of Aβ by proteolytic activities referred to as β and γ secretase, respectively. βAPP is also cleaved at Aβ16 by a third protease, α secretase, which may prevent amyloid deposition by bisecting the Aβ peptide. Tacrine, a cholinesterase inhibitor, has been shown to improve memory and cognitive functions in some patients with AD, and we have previously demonstrated that it significantly reduces the levels of the secretion of soluble βAPP fragments (sAPP) in cultured cells. In this study, we extended our studies by analysis of Aβ40 and Aβ42 and report that in a human neuroblastoma cell line tacrine reduced the levels of total Aβ, Aβ40 and Aβ42 in addition to sAPP. These inhibitory results cannot be attributed to a reduction in total βAPP synthesis as tacrine treatment did not cause a significant change in the rate of βAPP synthesis. Furthermore, significant toxicity was not observed in tacrine-treated cultures as determined by analysis of lactate dehydrogenase (LDH) in the conditioned media. Taken together, these results suggest that tacrine affects the processing of βAPP by alterations in βAPP trafficking and/or increased intracellular proteolysis. This study raises the possibility that tacrine may aid in the treatment of AD due to its effects on βAPP processing as well as by its effects on the cholinergic pathway.",
keywords = "β- Peptide, β-Amyloid precursor protein, Alzheimer's disease, Anticholinesterase, Neuroblastoma cell, Protein processing, Protein transport, THA",
author = "Debomoy Lahiri and Martin Farlow and Kumar Sambamurti",
year = "1998",
month = "11",
day = "26",
doi = "10.1016/S0169-328X(98)00236-8",
language = "English",
volume = "62",
pages = "131--140",
journal = "Brain Research",
issn = "0006-8993",
publisher = "Elsevier",
number = "2",

}

TY - JOUR

T1 - The secretion of amyloid β-peptides is inhibited in the tacrine- treated human neuroblastoma cells

AU - Lahiri, Debomoy

AU - Farlow, Martin

AU - Sambamurti, Kumar

PY - 1998/11/26

Y1 - 1998/11/26

N2 - The amyloid β-protein (Aβ) is an approximately 4 kD secreted protein normally found in human plasma and cerebrospinal fluid. Aβ is invariably deposited as insoluble amyloid fibrils in the brains of patients with Alzheimer's disease (AD), and there is increasing evidence that Aβ deposition plays an important role in AD pathogenesis. Aβ is released from the larger β-amyloid precursor protein (βAPP) through cleavage on the amino and carboxyl side of Aβ by proteolytic activities referred to as β and γ secretase, respectively. βAPP is also cleaved at Aβ16 by a third protease, α secretase, which may prevent amyloid deposition by bisecting the Aβ peptide. Tacrine, a cholinesterase inhibitor, has been shown to improve memory and cognitive functions in some patients with AD, and we have previously demonstrated that it significantly reduces the levels of the secretion of soluble βAPP fragments (sAPP) in cultured cells. In this study, we extended our studies by analysis of Aβ40 and Aβ42 and report that in a human neuroblastoma cell line tacrine reduced the levels of total Aβ, Aβ40 and Aβ42 in addition to sAPP. These inhibitory results cannot be attributed to a reduction in total βAPP synthesis as tacrine treatment did not cause a significant change in the rate of βAPP synthesis. Furthermore, significant toxicity was not observed in tacrine-treated cultures as determined by analysis of lactate dehydrogenase (LDH) in the conditioned media. Taken together, these results suggest that tacrine affects the processing of βAPP by alterations in βAPP trafficking and/or increased intracellular proteolysis. This study raises the possibility that tacrine may aid in the treatment of AD due to its effects on βAPP processing as well as by its effects on the cholinergic pathway.

AB - The amyloid β-protein (Aβ) is an approximately 4 kD secreted protein normally found in human plasma and cerebrospinal fluid. Aβ is invariably deposited as insoluble amyloid fibrils in the brains of patients with Alzheimer's disease (AD), and there is increasing evidence that Aβ deposition plays an important role in AD pathogenesis. Aβ is released from the larger β-amyloid precursor protein (βAPP) through cleavage on the amino and carboxyl side of Aβ by proteolytic activities referred to as β and γ secretase, respectively. βAPP is also cleaved at Aβ16 by a third protease, α secretase, which may prevent amyloid deposition by bisecting the Aβ peptide. Tacrine, a cholinesterase inhibitor, has been shown to improve memory and cognitive functions in some patients with AD, and we have previously demonstrated that it significantly reduces the levels of the secretion of soluble βAPP fragments (sAPP) in cultured cells. In this study, we extended our studies by analysis of Aβ40 and Aβ42 and report that in a human neuroblastoma cell line tacrine reduced the levels of total Aβ, Aβ40 and Aβ42 in addition to sAPP. These inhibitory results cannot be attributed to a reduction in total βAPP synthesis as tacrine treatment did not cause a significant change in the rate of βAPP synthesis. Furthermore, significant toxicity was not observed in tacrine-treated cultures as determined by analysis of lactate dehydrogenase (LDH) in the conditioned media. Taken together, these results suggest that tacrine affects the processing of βAPP by alterations in βAPP trafficking and/or increased intracellular proteolysis. This study raises the possibility that tacrine may aid in the treatment of AD due to its effects on βAPP processing as well as by its effects on the cholinergic pathway.

KW - β- Peptide

KW - β-Amyloid precursor protein

KW - Alzheimer's disease

KW - Anticholinesterase

KW - Neuroblastoma cell

KW - Protein processing

KW - Protein transport

KW - THA

UR - http://www.scopus.com/inward/record.url?scp=0032569990&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032569990&partnerID=8YFLogxK

U2 - 10.1016/S0169-328X(98)00236-8

DO - 10.1016/S0169-328X(98)00236-8

M3 - Article

VL - 62

SP - 131

EP - 140

JO - Brain Research

JF - Brain Research

SN - 0006-8993

IS - 2

ER -